International Clinical Trial: An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2021250022) titled 'An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)' on Oct. 6.

Study Type: Interventional

Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

Primary Sponsor: Tamura Shinichi

Condition: Advanced Non-small Cell Lung Cancer

Intervention: HLX43 2.0 mg/kg or 2.5 mg/kg IV Q3W.

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 06/10/2025

Target Sample Size: 20

Countries of Recruitment: China J...